Envoy Medical Inc. (COCH) Stock Forecast & Price Target
Envoy Medical Inc. · NASDAQ
$0.72+0.01 (+0.93%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Envoy Medical Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $2.00 to $2.00, so the covering firms are broadly aligned. The average target of $2.00 sits 179% above the current $0.72. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.07 next quarter toward $-0.22 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Envoy Medical Inc.
As of Sep, 2 of 2 firms rate COCH a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
COCH EPS & revenue forecast
EPS · NEXT QUARTER
$-0.07
Range $-0.09 – $-0.06 · 2 analysts
Next period, 2 analysts expect Envoy Medical Inc. to earn $-0.07 a share (range $-0.09 – $-0.06), versus — a year earlier. Full-year consensus is $-0.29, growing to $-0.22 the year after.
REVENUE · NEXT QUARTER
$77.5K
Range $55.0K – $100.0K · 2 analysts
Revenue is expected to reach $77.5K (range $55.0K – $100.0K). Full-year consensus is $250.0K, rising to $310.0K next year.
Top analysts covering Envoy Medical Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on COCH.
#1
Yi Chen
HC Wainwright & Co. · Rank #277
Buy
$2.00+179.1% to target
Overall win rate
33%
+ Follow
#2
Frank Takkinen
Lake Street · Rank #394
Buy
$6.00+737.3% to target
Overall win rate
26%
+ Follow
#3
Edward Woo
Ascendiant Capital · Rank #430
Buy
$9.50+1225.7% to target
Overall win rate
26%
+ Follow
#4
Carl Byrnes
Northland Capital Markets
Buy
$5.00+597.7% to target
Coverage
—
+ Follow
#5
EW
Edward Woo
Ascendiant
Buy
$9.50+1225.7% to target
Coverage
—
+ Follow
COCH stock forecast FAQ
What is COCH's average 12-month price target?+
The 2 analysts with a live target average $2.00 for Envoy Medical Inc. over the next 12 months, ranging from a $2.00 high to a $2.00 low.
Is COCH stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover COCH?+
2 analysts have an active rating on Envoy Medical Inc., and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering COCH?+
Among analysts who currently cover COCH, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #277). Their current call is Buy with a $2.00 target.
What is Envoy Medical Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.07 per share (range $-0.09 – $-0.06) across 2 analysts. Full-year EPS is projected at $-0.29, rising to $-0.22 the following year.
How much revenue is Envoy Medical Inc. expected to report next quarter?+
Consensus revenue is $77.5K (range $55.0K – $100.0K). Full-year revenue is projected at $250.0K, growing to $310.0K next year.
Have analysts been upgrading or downgrading COCH lately?+
As of Sep, 2 of 2 firms rate COCH a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their COCH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
LUCID CAPITAL MARKETS
